OncoMatch/Clinical Trials/NCT05462496
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Is NCT05462496 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including FOLFIRINOX and Ciprofloxacin for pancreatic cancer.
Treatment: FOLFIRINOX · Ciprofloxacin · Metronidazole · Pembrolizumab — A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Any prior radiation therapy ... for treatment of the patient's pancreatic tumor
Cannot have received: immunotherapy
Any prior ... immunotherapy ... for treatment of the patient's pancreatic tumor
Cannot have received: biologic ('targeted') therapy
Any prior ... biologic ('targeted') therapy for treatment of the patient's pancreatic tumor
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1500/µL; Platelets ≥100,000/µL; Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L (without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks)
Kidney function
Creatinine ≤1.5 × ULN OR measured or calculated creatinine clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN
Liver function
Total bilirubin ≤1.5 ×ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN; AST (SGOT) and ALT (SGPT) ≤2.5 × ULN
Normal organ and marrow function as defined below: ... (see above for full details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Icahn School of Medicine at Mount Sinai · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05462496 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages